Life Technologies Corp. v. Promega Corp.

E-Law Admin/ Februar 22, 2017/ Arzneimittelrecht Schweiz/ 0Kommentare

Life Technologies Corp. v. Promega Corp., 14-1538

In an infringement suit in which plaintiff sublicensed a patent, which claims a toolkit for genetic testing, for the manufacture and sale of the kits for use in certain licensed law enforcement fields worldwide, alleging a violation of section 271(f)(1) of the Patent Act, which prohibits the supply from the United States of ‘all or a substantial portion of the components of a patented invention’ for combination abroad, the Federal Circuit’s judgment, which determined that a single important component could constitute a substantial portion’ of the components of an invention under section 271(f)(1), is reversed where the supply of a single component of a multicomponent invention for manufacture abroad does not give rise to section 271(f)(1) liability.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2017/02/22

Judges

Court

  • United States Supreme Court

Counsel


e-Law Trainer

Share this Post

Hinterlasse einen Kommentar